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Summary Two polyclonal rabbit antibodies to epithelial membrane antogen (EMA), two mouse monoclonal
antibodies (E29 and HMFG-2), and a "cocktail" of these two monoclonals have been compared using an
indirect immunoperoxidase technique. Sections from 25 tissues (17 malignant and 8 benign), were examined.
The distribution of staining with each of these reagents was similar, but the polyclonal antibodies produced
stronger staining in colorectal carcinomas and lactating breast, whereas staining with the monoclonal
antibodies was stronger in non-neoplastic pleural mesothelium and in pulmonary alveolar cells. When the two
monoclonals were mixed there was no increase in staining intensity. E29 gave a "cleaner" result than HMFG-
2, with better discrimination between cells and stroma, and is highly suitable for routine diagnostic
histopathology.
Antibodies to human milk fat globule membranes
(HMFG) (Ceriani et al., 1977), have been shown to
react with normal and neoplastic epithelium in a
wide variety of sites (Heyderman et al., 1979;
Sloane et al., 1980a,b; 1982 Sloane & Ormerod,
1981; Gusterson et al., 1982; Bamford et al., 1983;
Heyderman et al., 1984a,b). The glycoprotein with
which these antisera react has been termed
epithelial membrane antigen (EMA), since the
staining in normal epithelial tissues, as well as in
well-to-moderately differentiated adenocarcinomas,
is mainly on the luminal or plasma membrane. The
antigen has been partially purified, and shown to
consist of a heterogeneous glycoprotein(s) of high
mol. wt. It has been suggested that carbohydrate
forms the major antigenic determinant, the
principal sugars being galactose and N-acetyl-
glucosamine (Ormerod et al., 1983).
All the breast carcinomas in the published series,
and the majority of adenocarcinomas from a
variety of sites, have been positive for EMA, while
sarcomas and neural tumours have been reported
to be negative. A few lymphomas (Sloane et al.,
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1983; Delsol et al., 1984) also show positivity. The
presence of EMA in a tumour is highly suggestive
of epithelial derivation, while its absence virtually
excludes breast origin. In tissue sections from some
patients, staining of the membrane of plasma cells
has also been seen (Dearnaley et al., 1983; Delsol et
al., 1984; Heyderman et al., 1984a).
Antisera to EMA have been used for the
detection of bone marrow and lymph node
metastases from breast carcinoma (Heyderman et
al., 1979; Sloane et al., 1980a,b; Gugliotta et al.,
1981; Dearnaley et al., 1981, 1983; Redding et al.,
1983), and for identification of malignant cells in
serous effusions (To et al., 1981; Epenetos et al.,
1982).
The value of EMA in tumour pathology has been
established by these investigations, but further
studies have been limited by shortage of sufficient
antisera suitable for immunocytochemistry. Two
monoclonal antibodies were raised against a
preparation of milk fat globule membranes (Cordell
et al., 1985 unpublished). In initial studies, one of
them, E29, gave excellent staining on fixed tissue
sections using an indirect immunoperoxidase
technique, at dilutions of 1:25-1:30. The other,
E103, stained known EMA-positive sections only
weakly, even when used undiluted.
The purpose of this study was to investigate the
distribution of staining using antibody E29 and to
compare it with an unpurified rabbit polyclonal
antibody (Ormerod, ICR, Sutton), an affinity-
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purified rabbit antibody raised by one of the
authors (TCR), a commercially available mono-
clonal antibody, HMFG-2 (Seward Laboratory,
Bedford) (Burchell et al., 1983), and a cocktail of
E29 and HMFG-2.
Methods and materials
Immunoperoxidase technique
An indirect immunoperoxidase technique was
employed, using peroxidase conjugates prepared
from affinity-purified sheep anti-rabbit or goat anti-
mouse immunoglobulin by periodate oxidation
(Nakane & Kawaoi, 1974). Endogenous peroxidase
was inhibited by a sequence of hydrogen peroxide,
periodic acid and potassium borohydride (Table I)
(Heyderman, 1979).
The appropriate dilution of all the antibodies was
assessed on a breast carcinoma used in our previous
EMA studies, and the dilution of the five anti-
EMA reagents was adjusted to give a similar
staining intensity. The unpurified rabbit antibody
(Dr Ormerod, ICR) was used diluted 1:1000, the
affinity-purified polyclonal at 1:25, E29 at 1:25,
and HMFG-2 at 1:10. The monoclonals were
mixed to give the same final dilutions.
Tissues and controls
All 25 tissues used in this study (Table II) were
chosen from cases found to be positive with the
affinity-purified rabbit anti-EMA antibody, so that
no positive control was required. Twenty-four were
formalin-fixed paraffin-embedded blocks from the
St Thomas Hospital files. The other specimen, a
paraffin-embedded first trimester placenta, had
been fixed in Bouin's solution.
As the object of this investigation was to
compare the distribution of staining with these four
antibodies, rather than to establish their specificity,
no negative 'absorbed' control was used. Use of
both the anti-rabbit and anti-mouse immuno-
globulin peroxidase conjugates in a number of
previous studies (Heyderman, 1983; 1984a,b;
Graham et al., 1985) had indicated that neither of
them showed evidence of anti-human activity.
Neither of them stained tissue sections when an
inappropriate or absorbed negative control serum
had been used.
Antibodies
A rabbit polyclonal antiserum to EMA was a
generous gift from Dr Ormerod (ICR, Sutton), and
the monoclonal antibody HMFG-2 was a gift from
Seward Laboratories.
Affinity-purified antibodies to EMA were
Table I Indirect immunoperoxidase technique
1. Dewax through xylene and alcohols to water
2. Bleach denatured haemoglobin with 6%
hydrogen peroxide in distilled water, and
commence inhibition ofendogenous
peroxidase. Wash off with tap water.
3. Complete inhibition ofendogenous
peroxidase with 2.5% periodic acid in
distilled water. Wash offwith tap water
4. Block aldehyde groups withfresh 0.02%
potassium borohydride in distilled water.
Wash offwith tap water. Wash offwith
PBS-azide pH 7.2 containing 0.02% sodium
azide and 1 1lml-1 ofdetergent (1% BRIJ
96, Sigma). Blot dry.
5. Apply 40pl 1st antibody diluted in 1%
ovalbumin PBS-azide, and cover with a
40 x 22 mm coverslip. Incubate in moist
chamber to prevent coverslip adhering too
strongly. Wash offwith PBS-azide.
6. Agitate in bath ofPBS-azide containing
1 ,u ml-1 of detergent. Blot dry
7. Apply 40pl ofperoxidase conjugate diluted
in 1% ovalbumin in azide-free PBS. Cover
with 40 x 22mm coverslip and incubate in
moist chamber. Wash off with PBS-azide
8 Agitate in PBS-azide bath containing
detergent
9. Incubate infresh diaminobenzidine (DAB)
(100mg in 200ml 0.03% hydrogen peroxide
in PBS-azide). Wash in tap water.
10. Counterstain in Mayer's haemalum; blue in
lithium carbonate; dehydrate, clear and
mount in Ralmount or other resinous
mountant.
5 min
5 min
2 min
lh
15 min
lh
15 min
5 min
Note 0.02% azide is required in the 1% ovalbumin in
PBS used for diluting first (specific) antibodies to be
stored at 4°C. It is optional in the PBS used for washing.
It should be omitted from 1% ovalbumin to be used for
diluting peroxidase conjugates since it is deleterious
(Richardson et al., 1983). Diluted conjugates may be
stored in aliquots at -20°C.
prepared at St Thomas Hospital (TCR), and the
monoclonal E29 at Oxford (JLC) using the
immunogen prepared as below (TCR).
Preparation ofEMA
Cream was separated from whole human milk by
low speed centrifugation (2000g, 20min). The lipid
layer was skimmed off and resuspended in saline
(NaCI0.15moll-1). The centrifugation and re-
suspension were repeated twice, and the lipid was
finally resuspended in saline to give a 33% w/v
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Table II Tissues used for study
Tumours
Carcinoma breast (3)
Carcinoma colon (2)
Carcinoma lung (4)
one each squamous, adeno-, large cell
and small cell anaplastic carcinoma
Renal cell carcinoma (2)
Carcinoma prostate
Carcinoma skin (2)
one squamous, and
one sebaceous carcinoma
Teratoma testis (MTI)
Carcinoma ovary (2)
Non-malignant tissues
Lactating breast
Benign prostate
Normal skin
Normal pituitary (PM material)
1st trimester placenta
3rd trimester placenta
Tonsil
Normal pancreas
The mixture was then thawed at 37°C and the
cloudy aqueous layer centrifuged at high speed
(40,000g 1 h) to yield a pellet of milk fat globule
membranes (Kobylka & Carraway, 1972). This was
centrifuged and resuspended three times in saline,
and used for the immunisation of rabbits.
Residual EMA in the lipid layer was extracted
with the mixture of monoclonals. When HMFG-2
The lipid was dissolved by adding a mixture of
equal volumes of chloroform and saline, shaking
and allowing to stand for 1 h at room temperature.
The upper aqueous layer was extracted again with
chloroform, and allowed to stand for a further
hour. The aqueous layer was then removed and
extracted twice with equivalent volumes of ether.
The slightly cloudy lower aqueous layer was
removed, and residual ether evaporated using
nitrogen gas. This delipidated extract in saline was
used for the immunisation of mice (Cordell et al.,
1985). The protein content of the milk fat globule
membrane preparation was determined by the
Coomassie blue dye-binding assay (Bradofrd, 1976).
Affinity chromatography
The EMA antisera raised in rabbits were purified
on an Affi-Gel 10 column. This is an agarose
containing active n-hydroxysuccinimide bonds
(Cuatrecasas & Parikh, 1972) (BioRad Laboratories,
Herts) to which purified EMA (non-chloroform/
ether extracted) had been bound. The antiserum
was applied to the column, left for 1 h, and un-
bound proteins and non-specific antibodies were
washed off with PBS (0.15moll-1, pH7.3). The
bound EMA-specific antibodies were eluted with
guanidine (3moll-1, pH3). The eluate containing
the affinity-purified antibody was immediately
dialysed against PBS to remove any remaining
guanidine which could have caused denaturation
of the antibodies.
Results
All of the sections showed positive staining with all
of the antibodies. The distribution of staining with
either of the four antibodies or with the
monoclonal 'cocktail' of E29 and HMFG-2 was
similar. Both in normal and neoplastic tissues there
was some heterogeneity of staining, less marked in
sections from non-neoplastic tissues. Where the
staining was on the luminal membrane of glandular
tissues it tended to be of fairly uniform intensity. In
the breast carcinomas most of the acini were
positive, including intracellular microacini,
whereas in the colorectal tumours only some acini
were stained. Cytoplasmic staining of tumours was
much more variable, with some morphologically
similar cells negative and others positive.
Discrimination between epithelial tissues and
stroma was excellent with the two polyclonal
antibodies and with E29. (Figures 1 and 2), but a
brownish tinge of staining in the connective tissue
was frequently found when HMFG-2 was used, and
with the mixture of monoclonals. When HMFG-2
was diluted further, the intensity of staining of the
test section of breast carcinoma showed an equal
decrease in staining of tumour and stroma. There
was no increase in staining intensity when the
'cocktail' was used, compared with the individual
monoclonal antibodies.
There were, however, minor differences. The
distribution of staining with polyclonal antibodies
in the breast carcinomas was mainly luminal
(Figure 3) with some cytoplasmic staining
particularly in more poorly differentiated areas.
With the monoclonal antibodies, there was a
tendency for the staining to be more cytoplasmic,
rather than confined to the luminal aspect of
malignant acini (Figure 4). Staining of the colonic
carcinomas (Figures 5 and 6) and the lactating
breast was stronger with the polyclonals (Figure 7)
than with the monoclonal antibodies (not shown).
The non-malignant mesothelium and alveolar
membranes surrounding the lung tumours were
stained more strongly with the monoclonal
antibodies, than with the polyclonals. All of the
antibodies stained the dense intradermal infiltrate358 E. HEYDERMAN et al.
Figure 1 Section of skin containing sebaceous glands
(left) and an invasive squamous carcinoma (right)
stained with monoclonal E29. Staining with polyclonal
antibodies to this tissue was indistinguishable ( x 40).
Figure 2 Skin containing eccrine sweat glands shows
intercellular canaliculi positive for EMA. Here again
results with monoclonal or polyclonal antibodies were
similar ( x40).
Figure 3 Invasive ductal carcinoma of the breast Figure 4 Another section of the tumour shown in
stained with unpurified anti-EMA (Dr Ormerod). The Figure 3 here stained with E29. There is more of a
positive staining is mainly on the luminal membranes cytoplasmic component (x 25).
(x25).E29 - A NEW MONOCLONAL ANTIBODY TO EMA 359 ~~~~~~~~~~~~~~'4
Figure 5 Moderately differentiated carcinoma of the Figure 6 Further section of the tumour shown in
colon stained with affinity-purified anti-EMA (STH). Figure 5 but stained with E29. When the dilutions
The staining is mainly luminal and in the necrotic were matched for staining of the breast carcinoma seen
debris, as is seen with antisera to carcinoembryonic in Figures 3 and 4, staining in the colonic tumour was
antigen (CEA). However, stains for EMA in colorectal weaker than with polyclonal antisera ( x25).
tumours are weaker than for CEA ( x 25).
4',,4. :., - o8 ;
Figure 7 Section of lactating breast stained with
purified polyclonal (x40).360 E. HEYDERMAN et al.
of plasma cells close to the squamous carcinoma of
the skin used for this study.
Discussion
The use of diagnostic histopathology of polyclonal
antibodies to EMA, a large glycoprotein present on
many benign and malignant epithelial membranes,
is well established. Polyclonal anti-EMA antibodies
have the disadvantages that they are available in
limited quantity, that the quality of the antisera
may vary from bleed to bleed, and that affinity-
purification yields are small. Monoclonal
antibodies, produced by the hybridoma system
(Kohler & Milstein, 1975), can be produced in large
amounts with substantially less inter-batch
variation.
However, monoclonal antibodies have the
disadvantage that if the determinant recognised is
shared by the tissues between which discrimination
is required (Kemshead et al., 1981), such unwanted
cross-reactivity cannot be diluted out, as is
sometimes possible with polyclonal antibodies. The
concentration of antibodies used in this study was
determined on the test breast carcinoma and the
intensity of staining of the tumour cells matched.
With an antibody like HMFG-2, which also stained
the stroma, further dilution reduced the intensity of
stromal staining, but also reduced the intensity of
tumour staining. As with polyclonal antibodies,
discrimination between positive and negative areas
may be lost when the antibody concentration of
monoclonals is increased too far (Ciocca et al.,
1983).
A possible approach is to use mixtures of well
characterised monoclonal antibodies as hybridoma
'cocktails'. Although this study did not result in any
increase in intensity of staining, it also did not
demonstrate any steric hindrance which might have
occurred with two antibodies reacting with what are
probably closely related epitopes. Further studies,
using cocktails of antibodies to EMA, carcino-
embryonic antigen and cytokeratin are in progress
for evaluation of apparently undifferentiated
(anaplastic) tumours.
Since monoclonal antibodies recognise only one
antigenic epitope, and polyclonal antibodies may
recognise a range of determinants, this may account
for differences in staining intensity and distribution.
However, these results and our subsequent use of
E29 in diagnostic histopathology, have not shown
any significant difference in distribution of staining
between E29 and our previously used affinity-
purified rabbit antibody. Like the polyclonal
antibodies, E29 stains decalcified tissues and can be
used for the detection of bone marrow metastases.
This reagent is now in routine use in our
departments in a panel of antibodies used for the
evaluation of tumours of uncertain origin.
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